Araris Biotech AG develops antibody-drug conjugate (ADC) linker technology for cancer therapies. The company, a spin-off from the Paul Scherrer Institute and ETH Zurich, focuses on creating a proprietary platform that enables payload attachment to antibodies without re-engineering.

Araris

Araris Biotech AG is pioneering a novel linker technology for antibody-drug conjugates (ADCs.) Our linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.

Innosuisse

Venture Kick

Redalpine

Schroder Adveq

VI Partners

btov Partners

4BIO Capital

Kinled Holding

Pureos Bioventures

Wille AG

Wille Finance

Follicular Lymphoma Innovation

Schroders Capital

Samsung Ventures

Araris Biotech AG

In case you missed it, we were recognized as one of the top seven innovative companies revolutionizing #AntibodyDrugConjugate (ADC) drug development in @Clarivate for Life Sciences & Healthcare’s Companies to Watch: Antibody Drug Conjugates report. For more information, download the full report here: https://bit.ly/4dlirZ6

Reminder that our Chief Scientific Officer, @Philipp Spycher, Ph.D., is speaking at the 2nd annual ADC Linker & Conjugation Summit in Boston, MA on Thursday, August 22nd at 12pm ET. He will be sharing insights about our development of highly stable multi-payload #AntibodyDrugConjugates (ADCs). For more information and to register, visit here: https://bit.ly/3qxC5hT

Excited to share that our CSO Philipp Spycher, Ph.D., was recently featured on a Drug Target Review webinar! Tune in to hear his insights on current advancements in immunotherapies, including #AntibodyDrugConjugates, for cancer treatment. Listen now: https://lnkd.in/ggyq7k6S

ADC technologies face challenges, including poor ADC exposure and solubility with limited chemical flexibility of the linker. Our #ADCTechnology generates homogenous, highly soluble, and stable ADCs with an antibody-like exposure profile at flexible drug load. In just one step, this approach has the potential to make a clinically meaningful difference for patients. Learn more: https://bit.ly/3WpB2fM

Our Co-Founder and Chief Scientific Officer, Philipp Spycher, Ph.D., will be speaking about the development of novel dual-payload antibody-drug conjugates (ADCs) at the 2nd annual ADC Linker & Conjugation Summit on Thursday, August 22nd at 12pm ET. For more information and to register, visit here: https://lnkd.in/eQWiftp7

Don’t forget to sign up for an insightful webinar where experts, including our own Co-founder & CSO, Philipp Spycher, Ph.D., will discuss immunotherapy advancements that are transforming cancer treatment. The panelists will explore the current landscape of immunotherapy research, including insights into recent developments and obstacles encountered within the field. To register for free and learn more, please visit here: https://lnkd.in/ggyq7k6S

We’re thrilled to be included as one of the top seven innovative companies revolutionizing antibody-drug conjugate (ADC) drug development in this report from Clarivate for Life Sciences & Healthcare. For more information, download the full report here: https://lnkd.in/eCSaAWtu

Our Co-Founder and Chief Scientific Officer, Philipp Spycher, Ph.D., will be a panelist on Drug Target Review's “Immunotherapy Advancements: Transforming Cancer Treatment” webinar on July 29th at 10am EDT. Join the webinar to hear more about Araris’ antibody-drug conjugates as a revolutionary approach in cancer treatment. To register for free and learn more, please visit here: https://lnkd.in/ggyq7k6S

In case you missed it, we presented data at the @American Association for Cancer Research (AACR) Annual Meeting 2024 on two novel dual TOP1i ADCs targeting HER2 and NaPi2b that showed high stability and high anti-tumor activity in mouse models. Read more here: https://bit.ly/3Kp6tBq

We’re pleased to announce we’ve appointed Ulf Grawunder, Ph.D. to our scientific advisory board. His wealth of knowledge and experience in the #ADC space will be instrumental as we continue to innovate our proprietary ADC technology and develop our pipeline of next-generation ADC therapies. Read more: https://bit.ly/3xgdUaT

COM:ARARISBIOTECH

Araris

Financials Not Available